A major advance for neuromedicine: the first clinical report on a successful chemogenetic gene therapy for epilepsy. Chemogenetics modifies cells to express cell signaling receptors which respond to a desired small molecule drug rather than to the body’s own signals; adding a new “knob of control” to biology. I am optimistic that this modality will have immense impact across all areas of medicine.
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2.
